Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-8 of 8 (Search time: 0.008 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2013European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Baccarani, M.; Deininger, M.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.; Cervantes, F.; Clark, R.; Cortes, J.; Guilhot, F.; Hansen-Hjorth, H.; Hughes, T.; Kantarjian, H.; Kim, D.; Larson, R.; Lipton, J.; Mahon, F.; Martinelli, G.; Mayer, J.; Muller, M.; et al.
2016Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsDeininger, M.; Hodgson, J.; Shah, N.; Cortes, J.; Kim, D.; Nicolini, F.; Talpaz, M.; Baccarani, M.; Müller, M.; Li, J.; Parker, W.; Lustgarten, S.; Clackson, T.; Haluska, F.; Guilhot, F.; Kantarjian, H.; Soverini, S.; Hochhaus, A.; Hughes, T.; Rivera, V.; et al.
2011Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cellsTang, M.; Gonen, M.; Quintas-Cardama, A.; Cortes, J.; Kantarjian, H.; Field, C.; Hughes, T.; Branford, S.; Michor, F.
2011Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsKantarjian, H.; Giles, F.; Bhalla, K.; Pinilla-Ibarz, J.; Larson, R.; Gattermann, N.; Ottmann, O.; Hochhaus, A.; Radich, J.; Saglio, G.; Hughes, T.; Martinelli, G.; Kim, D.; Shou, Y.; Gallagher, N.; Blakesley, R.; Baccarani, M.; Cortes, J.; le Coutre, P.
2009Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNetBaccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R.; Goldman, J.; Hehlmann, R.
2011Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid LeukemiaCortes, J.; Hochhaus, A.; Hughes, T.; Kantarjian, H.
2014Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyBaccarani, M.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Mongay, L.; Mone, M.; Ortmann, C.; Kantarjian, H.; Radich, J.; Hughes, T.; Cortes, J.; Guilhot, F.
2009Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R)Kantarjian, H.; Pasquini, R.; Levy, V.; Jootar, S.; Holowiecki, J.; Hamerschlak, N.; Hughes, T.; Bleickardt, E.; Dejardin, D.; Cortes, J.; Shah, N.